6533b7dafe1ef96bd126e19b
RESEARCH PRODUCT
Near-fatal asthma phenotype in the ENFUMOSA Cohort.
M. RomagnoliG. CaramoriF. BraccioniF. RavennaE. BarreiroN. M. SiafakasA. M. VignolaP. ChanezLeonardo M. FabbriA. Papi The Enfumosa Study Groupsubject
Hypersensitivity ImmediateMaleAllergyVital CapacityAnti-asthmatic AgentSeverity of Illness Indexlaw.inventionCohort StudiesLeukocyte CountlawRisk FactorsForced Expiratory Volumenear-fatal asthmaImmunology and AllergyMedicineAnti-Asthmatic AgentsMiddle AgedIntensive care unitInflammation near-fatal asthma severe asthma sputumPhenotypeFemalemedicine.symptomCohort studyAdultinflammation; near-fatal asthma; severe asthma; sputumsevere asthmamedicine.medical_specialtyPartial PressureImmunologyStatus AsthmaticusDrug Administration ScheduleInternal medicineSeverity of illnessHumansRisk factorGlucocorticoidsAsthmaSkin TestsInflammationbusiness.industrysputummedicine.diseaseAsthmarespiratory tract diseasesOxygeninflammationImmunologySputumPatient Compliancebusinessdescription
Summary Background Near-fatal asthma (NFA) is characterized by severe asthma attacks usually requiring intensive care unit admission. This phenotype of asthma has been studied mainly in acute conditions. Methods The aim of our study was to compare the clinical, functional and inflammatory characteristics of NFA patients with mild to severe asthmatics in stable conditions. We recruited 155 asthmatic patients from five centres of the European Network for Understanding Mechanisms of Severe Asthma: 67 patients with mild-to-moderate asthma controlled by low/medium doses of inhaled corticosteroids; 64 with severe asthma that, despite treatment with high doses of inhaled corticosteroids, long-acting β2-agonists and for 1/3 also with regular oral corticosteroids, had at least one asthma exacerbation in the previous year; 24 with an NFA episode in the previous 5 years in the absence of inclusion criteria for the previous groups. All the patients were examined in stable conditions. Results NFA patients were taking less corticosteroids and were less compliant to prescribed asthma medications than the other two groups of patients. Lung function, blood gases, atopic status, sputum and blood inflammatory cell count of NFA patients were similar to mild-to-moderate, but not severe, asthmatic patients. Conclusions In stable conditions patients with an NFA attack in the previous 5 years cannot be distinguished from patients with mild-to-moderate asthma, while they are different from severe asthmatics both in terms of lung function and of airway inflammation. The risk factor that characterizes this group of patients is reduced usage of prophylactic corticosteroids.
year | journal | country | edition | language |
---|---|---|---|---|
2007-01-01 |